$NSRX News

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma shares are trading lower after Citizens lowered its price target on the stock from $19 to $18.

Nasus Pharma shares are trading lower after Citizens lowered its price target on the stock from $19 to $18.

Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To EpiPen; Pivotal Trial Planned For !4

BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript

What's Going On With Nasus Pharma Stock On Wednesday

NSRX: NS002 Phase II Topline Results

Nasus Pharma Stock Hits 52-Week Low - Here's Why

Nasus Pharma shares are trading lower after the company reported results from its Phase 2 clinical study of NS002. The reported data is lower than January's interim data.

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

Nasus Pharma shares are trading lower after the company announced top line results from its Phase 2 clinical study of NS002, its investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. Also, the company plans to initiate a clinical study in Q4 2026.

Nasus Pharma's Topline Results From Phase 2 Study Of NS002 For Anaphylaxis Shows NS002 Achieved Significantly Faster And Higher Early Epinephrine Absorption Compared To Intramuscular Epipen Autoinjector

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

Nasus Pharma To Present Topline Analysis From Its Phase 2 Repeated Dose Clinical Study Of NS002

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

Nasus Pharma Announces Closing of $15.0 Million Private Placement